Compare RXRX & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXRX | BHC |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2021 | 1996 |
| Metric | RXRX | BHC |
|---|---|---|
| Price | $3.52 | $6.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | $7.32 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 25.0M | 1.7M |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.79 | ★ 423.08 |
| EPS | ★ N/A | N/A |
| Revenue | $74,681,000.00 | ★ $8,724,000,000.00 |
| Revenue This Year | N/A | $6.05 |
| Revenue Next Year | $26.91 | $0.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.77 | $4.33 |
| 52 Week High | $6.50 | $8.00 |
| Indicator | RXRX | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 44.78 | 63.75 |
| Support Level | $2.90 | $5.44 |
| Resistance Level | $3.88 | $7.04 |
| Average True Range (ATR) | 0.45 | 0.24 |
| MACD | -0.09 | 0.06 |
| Stochastic Oscillator | 4.00 | 85.40 |
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.